Format

Send to

Choose Destination
Int J Biochem Cell Biol. 2014 Jun;51:89-92. doi: 10.1016/j.biocel.2014.03.029. Epub 2014 Apr 6.

β-Thalassemia and Polycythemia vera: targeting chronic stress erythropoiesis.

Author information

1
Weill Cornell Medical College, Department of Pediatrics Hematology-Oncology, 515 E 71st Street, New York, 10021 NY, USA.
2
Weill Cornell Medical College, Department of Pediatrics Hematology-Oncology, 515 E 71st Street, New York, 10021 NY, USA. Electronic address: str2010@med.cornell.edu.

Erratum in

  • Int J Biochem Cell Biol. 2014 Oct;55:349.

Abstract

β-Thalassemia and Polycythemia vera are genetic disorders which affect the synthesis of red blood cells, also referred to as erythropoiesis. Although essentially different in clinical presentation - patients with β-thalassemia have an impairment in β-globin synthesis leading to defective erythrocytes and anemia, while patients with Polycythemia vera present with high hemoglobin levels because of excessive red blood cell synthesis - both pathologies may characterized by lasting high erythropoietic activity, i.e. chronic stress erythropoiesis. In both diseases, therapeutic strategies targeting chronic stress erythropoiesis may improve the address phenotype and prevent secondary pathology, such as iron overload. The current review will address the basic concepts of these strategies to reduce chronic stress erythropoiesis, which may have significant clinical implications in the near future.

KEYWORDS:

Chronic stress erythropoiesis; Iron metabolism; Macrophages; Polycythemia vera; β-Thalassemia

PMID:
24718374
PMCID:
PMC4083841
DOI:
10.1016/j.biocel.2014.03.029
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center